NUTX Nutex Health (NUTX) Insider Trading, Ownership & Congress Trades
Services · Services-business services, nec · CIK 0001479681
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
100
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $0 priced
What the filings say about NUTX
Insiders, 180 days
-$43.5K net sold
1 seller · 0% of sales under a 10b5-1 plan
Nutex Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Nutex Health Inc. insiders sold a net $43.5K of stock across 45 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 50.7% of the 400 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Saunders Scott J sold about $43.5K of NUTX on Sep 18, 2026, the largest insider sale at the company since 2022; 100 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 150 shares held after it.
- 3 other insiders bought within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jaumot Frank E bought about $14.0K of NUTX on Mar 20, 2026; 3 other insiders bought within 30 days and 100 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 15, 2022.
- The trade is 3.2% of the 7,765 shares held after it.
- 3 other insiders bought within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Hosseinion Warren bought about $23.7K of NUTX on Mar 19, 2026; 3 other insiders bought within 30 days and 100 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 32,137 shares held after it.
- 3 other insiders bought within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Spears Kelvin bought about $945 of NUTX on Mar 17, 2026; 3 other insiders bought within 30 days and 100 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 14, 2023.
- The trade is 2.9% of the 2,758 shares held after it.
- 3 other insiders bought within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer-Healthcare Montgomery Pamela W. bought about $7.0K of NUTX on Mar 13, 2026; 3 other insiders bought within 30 days and 100 funds added in the latest 13F quarter.45 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$43.5K over 180 days
-$43.5K over 90 days
more than 67% of Services
Congress
no House purchase disclosed in the last 12 months
Funds
100 funds bought in last quarter
more than 52% of Services
Revenue
+82.4% year over year
more than 93% of Services
Margin
8.1% net margin
more than 70% of Services
Buybacks
$50.7M repurchased, FY to 2026-06-30
more than 52% of Services
Short interest
29.9% of the float short (float per yahoo 2026-10-27) · 7.6 days to cover · settled 2026-10-15
more than 96% of Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NUTX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+78.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NUTX: institutional holders (13F)
13F holdings, latest reported quarter
451,310 sh
$77.1M
407,349 sh
$69.6M
237,414 sh
$40.6M
215,919 sh
$36.9M
132,049 sh
$22.6M
Congress trades in NUTX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NUTX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NUTX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.4M position · as of 2026-06-30
1.7%
CANTOR FITZGERALD EQUITY OPPORTUNITY FUND
$1.4M position · as of 2026-06-30
1.7%
Bushido Capital US SMID Cap Equity ETF
$2.0M position · as of 2026-07-31
1.1%
First Trust Dow Jones Select MicroCap Index Fund
$2.8M position · as of 2026-06-30
1.1%
Cambria Value and Momentum ETF
$945.2K position · as of 2026-07-31
0.9%
VictoryShares Small Cap Free Cash Flow ETF
$4.9M position · as of 2026-06-30
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Thomas T. Vo
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.9M
$4.6M
$787.8K
-42%
+22%
2024
$1.2M
$1.6M
$912.2K
-89%
+6%
2023
$1.0M
$1.0M
$577.4K
-91%
+3%
2021
$1.8M
$492.8K
$573.0K
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $43.5K sold by insiders over 180 days, 100 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NUTX financials
Revenue growth
+82.4%
XBRL, annual
Net margin
8.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$846.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NUTX
| FY Dec 2025 | $875.3M |
| FY Dec 2024 | $479.9M |
| FY Dec 2023 | $247.6M |
| FY Dec 2022 | $219.9M |
| FY Dec 2021 | n/a |
| Jun 2026 | $210.8M |
| Mar 2026 | $216.5M |
| Dec 2025 | $151.7M |
| Sep 2025 | $267.8M |
| Jun 2025 | $244.0M |
| Mar 2025 | $211.8M |
| Dec 2024 | $257.6M |
| Sep 2024 | $78.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+21.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NUTX
| FY Dec 2025 | +8.1% |
| FY Dec 2024 | +10.9% |
| FY Dec 2023 | -18.5% |
| FY Dec 2022 | -193.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | +31.2% |
| Mar 2026 | +21.6% |
| Dec 2025 | +7.8% |
| Sep 2025 | +20.7% |
| Jun 2025 | -7.3% |
| Mar 2025 | +10.0% |
| Dec 2024 | +23.9% |
| Sep 2024 | -11.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$274.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NUTX
| FY Dec 2025 | $245.6M |
| FY Dec 2024 | $20.8M |
| FY Dec 2023 | -$8.2M |
| FY Dec 2022 | $36.0M |
| FY Dec 2021 | $136.5M |
| Jun 2026 | $31.7M |
| Mar 2026 | $74.3M |
| Dec 2025 | $69.0M |
| Sep 2025 | $99.2M |
| Jun 2025 | $26.5M |
| Mar 2025 | $50.9M |
| Dec 2024 | -$341.0K |
| Sep 2024 | $6.2M |
At each fiscal year end
Single quarter
Debt to equity
0.10x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity NUTX
| FY Dec 2025 | 0.13x |
| FY Dec 2024 | 0.28x |
| FY Dec 2023 | 0.60x |
| FY Dec 2022 | 0.37x |
| FY Dec 2021 | 1.47x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.12x |
| Dec 2025 | 0.13x |
| Sep 2025 | 0.14x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.20x |
| Dec 2024 | 0.28x |
| Sep 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
7.06x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt NUTX
| FY Dec 2025 | 5.84x |
| FY Dec 2024 | 0.63x |
| FY Dec 2023 | 0.03x |
| FY Dec 2022 | 1.42x |
| FY Dec 2021 | 1.03x |
| Jun 2026 | 7.06x |
| Mar 2026 | 6.65x |
| Dec 2025 | 5.84x |
| Sep 2025 | 4.08x |
| Jun 2025 | 2.16x |
| Mar 2025 | 2.01x |
| Dec 2024 | 0.63x |
| Sep 2024 | 0.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+57.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NUTX
| FY Dec 2025 | +30.7% |
| FY Dec 2024 | +53.8% |
| FY Dec 2023 | -58.2% |
| FY Dec 2022 | -403.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | +57.2% |
| Mar 2026 | +36.8% |
| Dec 2025 | +30.7% |
| Sep 2025 | +63.9% |
| Jun 2025 | +37.9% |
| Mar 2025 | +61.5% |
| Dec 2024 | +53.8% |
| Sep 2024 | -54.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+19.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NUTX
| FY Dec 2025 | +9.0% |
| FY Dec 2024 | +9.9% |
| FY Dec 2023 | -11.0% |
| FY Dec 2022 | -102.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | +19.9% |
| Mar 2026 | +11.2% |
| Dec 2025 | +9.0% |
| Sep 2025 | +17.2% |
| Jun 2025 | +8.9% |
| Mar 2025 | +12.6% |
| Dec 2024 | +9.9% |
| Sep 2024 | -9.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+142.1%
operating income after a 20.7% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital NUTX
| FY Dec 2025 | +126.7% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +142.1% |
| Mar 2026 | +135.6% |
| Dec 2025 | +126.7% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+48.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NUTX
| FY Dec 2025 | +43.7% |
| FY Dec 2024 | +31.1% |
| FY Dec 2023 | -8.9% |
| FY Dec 2022 | -110.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | +48.8% |
| Mar 2026 | +41.3% |
| Dec 2025 | +43.7% |
| Sep 2025 | +62.4% |
| Jun 2025 | +47.8% |
| Mar 2025 | +46.1% |
| Dec 2024 | +31.1% |
| Sep 2024 | -2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
8.27x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing NUTX
| FY Dec 2025 | 16.88x |
| FY Dec 2024 | 3.43x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 6.76x |
| Mar 2026 | 7.34x |
| Dec 2025 | 16.88x |
| Sep 2025 | 5.36x |
| Jun 2025 | 12.73x |
| Mar 2025 | 3.71x |
| Dec 2024 | 3.43x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.3B
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value NUTX
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $168.5M |
| FY Dec 2023 | $18.1B |
| FY Dec 2022 | $185.2B |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.0B |
| Mar 2026 | $495.9M |
| Dec 2025 | $1.0B |
| Sep 2025 | $496.2M |
| Jun 2025 | $688.1M |
| Mar 2025 | $230.5M |
| Dec 2024 | $168.5M |
| Sep 2024 | $100.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+19.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield NUTX
| FY Dec 2025 | +21.1% |
| FY Dec 2024 | +12.1% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | +23.3% |
| Mar 2026 | +40.6% |
| Dec 2025 | +21.1% |
| Sep 2025 | +28.5% |
| Jun 2025 | +11.2% |
| Mar 2025 | +24.8% |
| Dec 2024 | +12.1% |
| Sep 2024 | +18.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.05x
P/E over trailing EPS growth of 158%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing NUTX
| FY Dec 2025 | 3.12x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.04x |
| Mar 2026 | 3.32x |
| Dec 2025 | 3.12x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $875.3M | $479.9M | $247.6M | $219.3M |
| Gross profit | $444.3M | $196.3M | $34.8M | $15.4M |
| Operating income | $275.6M | $130.7M | -$31.8M | -$406.6M |
| Net income | $70.8M | $52.1M | -$45.8M | -$424.8M |
| EPS (diluted) | 10.48 | 9.69 | -10.39 | -100.36 |
| Operating cash flow | $248.1M | $23.2M | $1.3M | $50.6M |
| Cash | $185.6M | $40.6M | $22.0M | $34.3M |
| Long-term debt | $29.2M | $22.5M | $26.3M | $23.1M |
| Buybacks | $5.0M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
NUTX Stock Sonar score 6/7 axes
Find similar shapesCompareNUTX ranks highest on profitability (96th percentile) and growth (93rd), and lowest on risk and compliance (10th), among Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NUTX filings, in plain words
Are Nutex Health insiders buying or selling NUTX?
In the 180 days to 2026-10-28, Nutex Health insiders were net sellers, a net $43.5K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Nutex Health insiders were net sellers of NUTX, a net $43.5K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
